Share on LinkedInShare on LinkedIn

ARTICLE · 12 APRIL 2013

Federal Circuit Affirms Injunction Against Impax Labs And Bars Generic Introduction

Analyzing an injunction preventing a generic pharma house from introducing a new generic drug, the U.S. Court of Appeals for the Federal Circuit upheld a lower court's decision.

United StatesIntellectual Property

Analyzing an injunction preventing a generic pharma house from introducing a new generic drug, the U.S. Court of Appeals for the Federal Circuit upheld a lower court's decision to issue equitable relief, finding that the generic pharma failed to file a timely appeal against an injunction. In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation, No. 12-1280 (Fed. Cir., Feb. 1, 2013) (O'Malley, J.)

In 2007, shortly after Cephalon filed a New Drug Application for AMRIX®, Impax, Mylan Inc. and Mylan Pharmaceuticals (Mylan), and Par Pharmaceutical, among others, filed Abbreviated New Drug Applications seeking U.S. Food and Drug Administration approval to make and sell generic versions. Cephalon sued for patent infringement and on the last day of trial settled with Impax. The settlement agreement granted a non-exclusive license in the patents that cover AMRIX® and controlled the timing of Impax's entry into the generic market.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from